TP53 and mantle cell lymphoma: Furthermore, European groups have been instrumental in the identification of the molecular biology and genome and epigenomic alterations of MCL subtypes68 and specific molecular high-risk groups of patients, particularly defined by the presence of mutations of TP53, but also other genetic aberrations, including KMT2D mutations and CDKN2A deletions.69–71